Form 4: 89bio Director's Options Converted in Roche Merger

Kathleen LaPorte's stock options in 89bio, Inc. were converted into cash and contingent value rights following the company's acquisition by Roche Holdings, Inc. for $14.50 per share plus CVRs.

Summary

• 89bio, Inc. was acquired by Roche Holdings, Inc. through its wholly-owned subsidiary Bluefin Merger Subsidiary, Inc.
• The acquisition was completed on October 30, 2025, following a tender offer for all outstanding shares of 89bio common stock.
• Shareholders received an offer price of $14.50 per share in cash (the 'Closing Amount') plus one non-tradeable Contingent Value Right (CVR) representing the right to receive up to an aggregate of $6.00 per share upon the achievement of specified milestones.
• Kathleen LaPorte, a Director of 89bio, had her outstanding stock options fully vested and converted as part of the merger agreement.
• Options with an exercise price below the $14.50 Closing Amount received cash equal to the difference between the Closing Amount and the exercise price, plus one CVR per share.
• Options with an exercise price between $14.50 and $20.50 (Out of the Money Options) received CVRs and potential future cash payments based on milestone achievements, but no upfront cash from the Closing Amount.
• Options with an exercise price equal to or greater than $20.50 were cancelled immediately prior to the merger without any payment.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, providing a clear exit for shareholders and eligible option holders with an upfront cash payment and potential future upside via CVRs. While some options were cancelled without payment, the overall transaction is a positive resolution for the company and its investors.

Positives

• The merger provides 89bio shareholders with a definitive cash payment of $14.50 per share.
• Shareholders and eligible option holders also receive potential upside through Contingent Value Rights (CVRs) of up to $6.00 per share, tied to future milestone achievements.
• All outstanding stock options for the reporting person became fully vested and exercisable prior to the merger, ensuring their value was addressed in the transaction.
• The acquisition by Roche, a major pharmaceutical company, suggests a strategic validation and value for 89bio's assets or pipeline.

Negatives

• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment, resulting in a loss for holders of those specific options.
• The CVRs are non-tradeable, limiting liquidity and requiring holders to wait for milestone achievements for potential additional value.
• The reporting person no longer holds any derivative securities in 89bio, Inc. following the transaction.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of specified milestones, which may not occur.
• Holders of Out of the Money Options (exercise price between $14.50 and $20.50) will only receive value from CVRs if milestones are met and the combined value exceeds their exercise price.

Future Outlook

The filing details the completed acquisition of 89bio by Roche, indicating 89bio will operate as a wholly-owned subsidiary. The future outlook for former 89bio shareholders and option holders is tied to the potential achievement of CVR milestones.

Industry Context

This acquisition by Roche Holdings, Inc. of 89bio, Inc. reflects ongoing consolidation and strategic investments within the biotechnology and pharmaceutical sectors. Larger pharmaceutical companies often acquire smaller biotech firms to gain access to promising pipelines, technologies, or market segments, particularly in areas like metabolic diseases or liver disorders, which 89bio's pipeline likely addresses. The use of CVRs is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks/rewards.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in biotech acquisitions is a common practice, seen in deals like Bristol-Myers Squibb's acquisition of Celgene or Merck's acquisition of Acceleron Pharma, where CVRs are used to provide additional value tied to regulatory approvals or sales milestones of specific drug candidates.
• The offer structure of an upfront cash payment plus CVRs is standard for deals where the target company has significant pipeline assets with future value uncertainty.

Stakeholder Impact

• Shareholders: Received $14.50 per share in cash plus CVRs, providing a liquidity event and potential future value.
• Option Holders (like Kathleen LaPorte): Options converted into cash and/or CVRs, with some deep out-of-the-money options cancelled without value.
• Employees (of 89bio): The company is now a wholly-owned subsidiary of Roche, which could lead to changes in corporate structure, benefits, or roles, though not explicitly detailed here.
• Roche Holdings, Inc.: Successfully acquired 89bio, expanding its portfolio.

Next Steps

• Monitoring the achievement of specified milestones for the Contingent Value Rights (CVRs) to determine potential additional payments.
• Integration of 89bio, Inc. into Roche Holdings, Inc. as a wholly-owned subsidiary.

Key Dates

Recommendation

The company has been acquired, and its shares are no longer publicly traded under ETNB. For former shareholders, the recommendation would be to 'hold' the CVRs if they believe the milestones will be met, as there is no public market for them. For new investors, the stock is no longer available for purchase.

Keywords

89bio, ETNB, Roche Holdings, Merger, Acquisition, Tender Offer, Contingent Value Rights, CVR, Stock Options, Beneficial Ownership, SEC Form 4, Biotechnology, Pharmaceuticals